ThomasWMalpassMD

PubMed

• 50 citations
  Combined weekly topotecan and biweekly bevacizumab in women with platinum‐resistant ovarian, peritoneal, or fallopian tube cancer
  Kathryn F. McGonigle, Howard G. Muntz, Jacqueline Vuky, Pamela J. Paley, Dan S. Veljovich, Benjamin E. Greer, Barbara A. Goff, Heidi J. Gray, T. W. Malpass> ;Cancer. 2011 Aug 15
• 10 citations
  Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-small Cell Lung Cancer
  Martin J. Edelman, Gregory A. Otterson, Joseph W. Leach, T. W. Malpass, Ravi Salgia, Dennie V. Jones, Tarak D. Mody, Ramaswamy Govindan> ;Journal of Thoracic Oncology. 2011 Apr 1
• 4 citations
  Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma
  Howard G. Muntz, T. W. Malpass, Kathryn F. McGonigle, Mandy D. Robertson, Paul L. Weiden> ;Cancer. 2008 Aug 1
• Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (OC).
  McGonigle KF, Muntz HG, Vuky JL, Paley PJ, Veljovich DS, Gray HJ, Malpass TW> ;J. Clin. Oncol.. 2008-05-20
• 28 citations
  Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma.
  Jacqueline Vuky, Christina Isacson, Mehran Fotoohi, Jason dela Cruz, Henry Otero, Vincent J. Picozzi, Thomas W. Malpass, David M. Aboulafia, Andrew Jacobs> ;Investigational New Drugs. 2006 Jan 13
• 3 citations
  Decreased Numbers of Platelet α-Adrenergic Binding Sites in Diabetes Mellitus
  R. M. Spalding, W. K. Ward, Thomas W. Malpass, J. R. Stratton, Jeffrey B. Halter, Daniel Porte, M. A. Pfeifer> ;Diabetes Care. 1986 May 1
• 38 citations
  Variations in circulating catecholamines fail to alter human platelet alpha-2-adrenergic receptor number or affinity for [3H]yohimbine or [3H]dihydroergocryptine.
  Michael A. Pfeifer, K. Ward, Thomas W. Malpass, John R. Stratton, Jeffrey B. Halter, M. Evans, H Beiter, Laurence A. Harker, Daniel Porte> ;The Journal of Clinical Investigation. 1984 Sep 1
• 161 citations
  Platelet-derived growth factor in vivo: levels, activity, and rate of clearance
  Daniel F. Bowen-Pope, Thomas W. Malpass, David M. Foster, Russell Ross> ;Blood. 1984 Aug 1
• 57 citations
  Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis.
  Samuel A. Burstein, Thomas W. Malpass, Esther Yee, Marshall E. Kadin, Malcolm Brigden, John W. Adamson, Laurence A. Harker> ;British Journal of Haematology. 1984 Jul 1
• 43 citations
  Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders.
  Thomas W. Malpass, B. Savage, S. R. Hanson, S. J. Slichter, Laurence A. Harker> ;The Journal of Laboratory and Clinical Medicine. 1984 Jun 1
• 9 citations
  Platelet adenine nucleotide levels in patients with Dacron vascular prostheses.
  Brian Savage, Thomas W. Malpass, John R. Stratton, Laurence A. Harker> ;Thrombosis Research. 1983 Nov 15
• 78 citations
  Studies of platelet factor 4 and beta thromboglobulin release during exercise: lack of relationship to myocardial ischemia.
  John R. Stratton, Thomas W. Malpass, James L. Ritchie, M A Pfeifer, Laurence A. Harker> ;Circulation. 1982 Jul 1
• 167 citations
  Studies of human plate alpha-granule release in vivo
  JC Files, Thomas W. Malpass, Esther Yee, James L. Ritchie, Laurence A. Harker> ;Blood. 1981 Sep 1
• 39 citations
  Prevention of acquired transient defect in platelet plug formation by infused prostacyclin
  Thomas W. Malpass, S. R. Hanson, Brian Savage, Eugene A. Hessel, Laurence A. Harker> ;Blood. 1981 Apr 1
• 556 citations
  Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release.
  Laurence A. Harker, Thomas W. Malpass, Herman E. Branson, Eugene A. Hessel, Sherrill J. Slichter> ;Blood. 1980 Nov 1
• Join now to see all